A full review of the device history record for this device has been carried out with no anomalies identified; product was manufactured and released for sale in accordance with specification.There is no info to suggest that the device has not met the final release criteria.From a review of the ifu, the warnings and precautions state: long-term efficacy of aorfix has not been established.Consequently, pts should be followed up routinely, and monitored for endoleak.Aneurysm growth and evidence of device migration.Common iliac arteries of aneurysmal or near aneurysmal proportions may lead to an endoleak.Potential adverse events related to the procedure or device malfunction include, but are not limited to endoleak; the risk analysis has been reviewed and type 1b endoleak is listed in lombard medical's hazard analysis.No further updates required.In this case, type 1b endoleak is a result of continuing aneurysm disease leading to dilation of the neck, which falls within the clinical expectations.The risk/benefit remains acceptable however lombard medical will continue to track and trends in accordance to quality system procedures.There is no info to suggest malfunction of the implant.Lombard medical not intends to close this complaint.
|